Sionna Therapeutics, Inc. — Investor Relations & Filings

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for cystic fibrosis (CF). The company's approach focuses on normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its core strategy involves advancing a pipeline of small molecules engineered to directly stabilize the CFTR protein's nucleotide-binding domain 1 (NBD1). This targets the underlying protein defect caused by the F508del mutation, the most common genetic cause of CF. Sionna is also developing a portfolio of complementary CFTR modulators designed to work synergistically with its NBD1 stabilizers. The company's goal is to restore CFTR function to near-normal levels, aiming to significantly improve clinical outcomes for people with CF.